Vaxcyte (PCVX) Total Liabilities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Total Liabilities data on file, last reported at $352.3 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 97.83% year-over-year to $352.3 million in Q1 2026; TTM through Mar 2026 was $352.3 million, a 97.83% increase from a year earlier, with the FY2025 full-year figure at $317.2 million, up 54.36% from the prior year.
• Total Liabilities for Q1 2026 stood at $352.3 million, up from $317.2 million in the prior quarter.
• Over the last five years, Total Liabilities for PCVX reached as high as $352.3 million in Q1 2026 and fell as low as $43.2 million in Q1 2022.
• Historically, Total Liabilities has averaged $147.3 million across 5 years, with a median of $107.3 million in 2024.
• Across the five-year window, Total Liabilities slipped 22.09% in 2022 and soared 218.56% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $52.6 million in 2022, then surged by 218.56% to $167.4 million in 2023, then rose by 22.72% to $205.5 million in 2024, then soared by 54.36% to $317.2 million in 2025, then rose by 11.06% to $352.3 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $352.3 million in Q1 2026, $317.2 million in Q4 2025, and $278.7 million in Q3 2025.